LDI 200

Drug Profile

LDI 200

Alternative Names: LDI-200

Latest Information Update: 19 Jan 2007

Price : $50

At a glance

  • Originator Milkhaus Laboratory
  • Class Analgesics; Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Preleukaemia; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Jan 2007 Discontinued - Phase-II for Acute myeloid leukaemia in USA (PO)
  • 19 Jan 2007 Discontinued - Phase-II for Prostate cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top